Statute Details
- Title: Health Products (Therapeutic Products) Regulations 2016
- Act Code: HPA2007-S329-2016
- Type: Subsidiary legislation (SL)
- Status: Current version (as at 27 Mar 2026)
- Enacting Act (context): Health Products Act (HPA) 2007
- Primary Subject Matter: Regulation of manufacture, import, supply, presentation, and registration of therapeutic products in Singapore
- Key Parts: Part 1 (Preliminary); Part 2 (Manufacture & Import); Part 3 (Supply); Part 4 (Presentation); Part 5 (Registration); Part 6 (Duties & Obligations); Part 7 (Exceptions—without licence); Part 8 (Exceptions—without registration); Part 8A (Emergency therapeutic products); Part 9 (Miscellaneous)
- Key Provisions (from extract): Reg. 2 (definitions); Reg. 3 (scope/exclusions, including clinical research material); Regs. 4–6 (manufacturer/importer licences and psychotropic imports); Regs. 11–17 (retail supply and dispensing controls); Regs. 19–21 (trade descriptions and information); Regs. 22–29 (registration, patent-related issues, confidentiality, exclusivity); Regs. 30–45 (recordkeeping, reporting, recall, risk management); Regs. 46–57 (exceptions to licensing); Regs. 58–60A (exceptions to registration and emergency products)
- Related Legislation (listed): Dental Registration Act 1999; Health Products Act; Healthcare Services Act 2020; Medical Registration Act 1997; Pharmacists Registration Act 2007
What Is This Legislation About?
The Health Products (Therapeutic Products) Regulations 2016 (“Therapeutic Products Regulations”) are the detailed regulatory rules that operationalise Singapore’s Health Products framework for therapeutic products. In plain terms, they set out who may manufacture, import, wholesale, and retail therapeutic products; what licences and registrations are required; what information must be provided to consumers and healthcare professionals; and what compliance duties apply to regulated entities.
The Regulations also address higher-risk categories and controlled substances. For example, they contain specific controls for therapeutic products containing psychotropic substances, including licensing and export-related restrictions. They further regulate certain medicines (such as codeine cough preparations) through additional supply restrictions, reflecting public health and misuse concerns.
Finally, the Regulations establish a product governance system: therapeutic products must generally be registered (subject to exceptions), and registrants must maintain data integrity and risk management obligations. The Regulations also include mechanisms for confidentiality of supporting information, disclosure rules, and registration exclusivity—issues that are central to innovative product applications and market access.
What Are the Key Provisions?
1) Scope, definitions, and exclusions (Part 1). The Regulations begin with definitions and a scope clause. Regulation 2 provides that definitions apply unless the context requires otherwise. Regulation 3 is crucial because it clarifies what the Regulations do not cover. The extract indicates that the Regulations do not apply to therapeutic products that are clinical research material (as defined in the Regulations). This matters for practitioners because it delineates the boundary between regulated “therapeutic products” for general supply and materials used in clinical research contexts.
2) Licensing for manufacture and import (Part 2). Part 2 sets licensing requirements. Regulation 4 requires conditions for the issue of a manufacturer’s licence; Regulation 5 similarly governs the issue of an importer’s licence. These provisions are the gateway controls: without the relevant licence, regulated activities are generally prohibited, subject to exceptions later in the Regulations.
Regulation 6 introduces additional requirements for importing therapeutic products containing psychotropic substances. While the extract does not reproduce the full text, the structure signals that psychotropic-containing products are treated as a special category, likely requiring enhanced compliance, documentation, and possibly additional approvals. For counsel advising importers, this is a key compliance risk area: a general importer’s licence may not be sufficient for psychotropic products without meeting the specific regulatory conditions.
3) Supply controls: wholesale, retail, dispensing, and controlled medicines (Part 3). Part 3 is the operational heart of day-to-day compliance. Regulation 7 sets requirements for purposes of section 17 of the Health Products Act, which likely frames what “supply” entails and the conditions under which supply is lawful. Division 1 then addresses wholesale supply. Regulations 8–10 cover export of psychotropic-containing therapeutic products, export of codeine cough preparations, and wholesale supply of therapeutic products containing ingredients listed in the Second Schedule. These provisions show that the Regulations do not only regulate domestic supply; they also regulate cross-border movement of certain medicines.
Division 2 addresses retail supply of registered therapeutic products. Regulations 11–13 distinguish between categories of medicines (prescription-only medicine, pharmacy-only medicine, etc.) and regulate how they may be supplied. Regulations 12 and 13 are particularly relevant to healthcare settings: supply by administration and supply by retail sale are treated differently, reflecting the role of healthcare professionals and the need for appropriate safeguards.
Regulation 14 imposes restrictions on retail supply of codeine cough preparations. This is a targeted control that practitioners should treat as a “red flag” provision for pharmacy compliance programmes, staff training, and recordkeeping. Regulation 15 addresses supply of general sale list medicine by retail sale vending machine, indicating that even low-risk medicines are regulated when supplied through automated channels.
Division 3 adds further requirements: Regulation 16 requires records of supply of prescribed therapeutic products, and Regulation 17 governs supply by dispensing therapeutic products. Together, these provisions support traceability and post-market enforcement.
4) Presentation and consumer-facing compliance (Part 4). Part 4 focuses on how therapeutic products are presented. Regulation 19 addresses trade descriptions. Regulation 20 requires information to be provided with therapeutic products. Regulation 21 provides corrective measures where there is contravention of trade descriptions or failure to provide prescribed information. For practitioners, this is a compliance area that often intersects with labelling, packaging, marketing claims, and regulatory submissions. It is also a frequent source of enforcement action because it can be triggered by relatively straightforward documentation or labelling failures.
5) Registration of therapeutic products and patent-related issues (Part 5). Part 5 establishes the registration regime. Regulation 22 sets requirements for registration. Regulation 23 addresses whether a therapeutic product is subject to patent, and Regulation 24 provides for cancellation of registration where there is a patent dispute. Regulation 24A introduces a prescribed time for cancellation of registration for non-payment of a retention fee, which is important for maintaining market authorisation.
Regulation 25 creates offences for making false declarations—an integrity provision that protects the registration system from fraudulent or inaccurate submissions. Regulations 26–27 provide protection of confidential supporting information relating to innovative therapeutic product applications, but Regulation 27 identifies circumstances where such protection does not apply. This is a sophisticated area: it balances innovation incentives with transparency and regulatory fairness.
Regulation 28 governs disclosure of information on applications for registration. Regulation 29 addresses registration exclusivity, which is particularly relevant to innovative products and follow-on applicants. Practitioners should read these provisions together to understand (i) what information is protected, (ii) when it can be disclosed, and (iii) how exclusivity affects subsequent registrations.
6) Ongoing duties: records, adverse effects, recall, and risk management (Part 6). Part 6 imposes continuing obligations on manufacturers, importers, wholesalers, and registrants. Division 1 includes general duties: Regulation 30 requires compliance with enforcement requirements; Regulations 31–33 require maintenance of records of manufacture, receipt and supply, and defects and adverse effects; Regulations 34 and 35 require reporting of defects/adverse effects and notification of the Authority concerning recall. These provisions are central to pharmacovigilance and quality assurance.
Division 2 then sets duties specific to licensees (Regulations 36–41), including duties of licensed manufacturer, importer, wholesaler, a “responsible person,” and offences for contravention. Regulation 41 addresses changes affecting a licence, which is critical for corporate restructuring, changes in premises, or changes in key personnel.
Division 3 imposes duties specific to registrants (Regulations 42–45). Regulation 42 concerns changes concerning registered therapeutic product. Regulation 43 requires information on the validity of data submitted to or considered by the Authority. Regulation 44 requires submission of benefit-risk evaluation reports. Regulation 45 imposes a duty to carry out a risk management plan. For practitioners, these provisions confirm that registration is not a one-off event; it is a continuing obligation tied to post-market evidence and risk mitigation.
How Is This Legislation Structured?
The Regulations are organised into nine parts, moving from foundational concepts to licensing and supply, then to product presentation and registration, and finally to ongoing compliance and exceptions.
Part 1 covers citation, commencement, definitions, and scope (including exclusions such as clinical research material). Part 2 regulates manufacture and import through licensing requirements, including special rules for psychotropic substances. Part 3 regulates supply across wholesale, retail, dispensing, and wholesaler licensing, with additional restrictions for controlled medicines. Part 4 addresses trade descriptions and required information, including corrective measures. Part 5 sets registration requirements, patent-related cancellation, confidentiality, disclosure, and exclusivity. Part 6 imposes duties and obligations, including recordkeeping, adverse event reporting, recall notification, and risk management. Part 7 provides exceptions allowing certain activities without a manufacturer’s/importer’s/wholesaler’s licence. Part 8 provides exceptions allowing supply without registration. Part 8A introduces an emergency framework for emergency therapeutic products. Part 9 contains miscellaneous provisions such as certificates and quality surveillance.
Who Does This Legislation Apply To?
The Regulations apply to persons and entities involved in the manufacture, import, supply, presentation, and registration of therapeutic products in Singapore. In practice, this includes licensed manufacturers, licensed importers, licensed wholesalers, retail pharmacies, and registrants (typically product authorisation holders). It also affects healthcare service licensees and pharmacists, particularly where exceptions permit certain activities without full licensing or registration.
Because the Regulations contain both licensing and registration regimes, applicability depends on the activity being performed and the product category. For example, psychotropic-containing products trigger additional import and export controls. Similarly, codeine cough preparations are subject to retail supply restrictions. Practitioners should therefore assess both who is acting and what therapeutic product is involved.
Why Is This Legislation Important?
For legal practitioners, these Regulations are important because they translate the Health Products Act into enforceable operational requirements. They create compliance duties that are measurable and auditable: licences for manufacturing/importing/wholesale supply, registration for therapeutic products, labelling and information obligations, and recordkeeping and reporting duties.
From a risk management perspective, the Regulations are significant because they connect regulatory compliance to patient safety and market integrity. The recordkeeping and adverse effects provisions (Regulations 31–35) support pharmacovigilance and enable the Authority to respond to safety signals. The recall notification duty is particularly consequential: failure to notify can create both regulatory exposure and potential civil liability risks.
Commercially, the registration and confidentiality provisions (Regulations 22–29) affect market access and competitive strategy. Patent-related cancellation provisions and registration exclusivity rules can determine whether and when follow-on products may be authorised. The confidentiality regime for innovative applications also influences how companies structure their submissions and manage information sharing.
Related Legislation
- Health Products Act 2007
- Healthcare Services Act 2020
- Medical Registration Act 1997
- Pharmacists Registration Act 2007
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Therapeutic Products) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.